health biotech news today obesity drugs glp-1 Lilly launches pill, kicking off showdown with Novo Nordisk Eli Lilly's Obesity Pill Shows

2,3 Against this backdrop, oral GLP-1 receptor agonists are emerging as an increasingly important area of focus, as companies look to extend growth beyond injectables and broaden access to obesity care

AOD-9604 Dosing AOD-9604 is administered as a daily subcutaneous injection

Axis 2: Clinical Appropriateness The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends GLP-1 receptor agonist therapy for adults with a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater with at least one weight-related comorbidity, after a structured assessment 11

It designates which substances and methods are prohibited both in- and out-of-competition and which substances are banned in particular sports

PMID 34844587